Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced a collaboration with Atigeo™, a compassionate technology company that turns science into products and services for a wiser world. Together, Emdeon and Atigeo plan to explore the use of intelligent analytics layered on top of petabytes of healthcare data to improve health outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59755-emdeon-and-atigeo-intelligent-analytics-for-health-outcomes-himss13
For the millions who suffer from Gastroesophageal Reflux Disease (GERD), a study published today in the New England Journal of Medicine (NEJM) provides clinical evidence of safety and effectiveness for a new, FDA-approved medical device. Torax Medical’s LINX® Reflux Management System was studied in a controlled, prospective, multicenter trial involving 14 U.S. and European medical centers as part of the FDA pre-market approval process. The patients were evaluated before and after treatment to determine the effect of the LINX System on their GERD using pre-defined success criteria, which included reduction of esophageal acid, improvement in quality of life and elimination of reflux medications.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60077-torax-medical-linx-reflux-management-system-clinical-study-published
SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy.
“With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Emdeon Inc., a leading provider of revenue and payment cycle management and clinical information exchange solutions, today announced the launch of Emdeon EDGE™, an integrated, technology-enabled solution that includes complete payment integrity and cost containment services designed to help detect improper healthcare claims and prevent inaccurate payments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/48121-emdeon-edge-payment-integrity-cost-management
Reproductive Medicine Associates of New Jersey (http://www.rmanj.com) today presented interim findings from its BEST (Blastocyst Euploid Selective Transfer) trial, the first well-controlled clinical trial comparing in vitro fertilization (IVF) pregnancy rates in a group of women receiving a single embryo transfer (SET) with comprehensive chromosome screening (CCS) with a group receiving traditional morphology-based double embryo transfer (DET). The findings were presented at the American Society for Reproductive Medicine 68th Annual Meeting in San Diego, October 20-24, 2012.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58883-rmanj-best-trial-results-ivf-pregnancy-rates-women-asrm-annual-meeting
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that subscribers to Epilog.us can now access the latest information related to Practice Management & Epilepsy at http://www.Epilog.us. Led by Dr. Aatif Husain, Director of the Clinical Neurophysiology Fellowship, Professor of Medicine, Division of Neurology, Duke University Medical Center, and Dr. John Stern, Co‐Director of the Seizure Disorder Center and Professor of Neurology at the David Geffen School of Medicine at UCLA, areas of focus include: the importance of billing code accuracy; commonly utilized billing codes in epilepsy and neurology; and epilepsy quality measures from the American Academy of Neurology (AAN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58062-upsher-smith-epilog-us-practice-management-epilepsy-resources-available
Avon celebrated the brand’s latest innovation, ANEW Clinical Pro Line Eraser Treatment, with flash mobs coast to coast in five cities, including New York, Chicago, Atlanta, Dallas and Los Angeles. Professional ballroom dancer Karina Smirnoff led the moves and wowed the crowd in Los Angeles. Avon Representatives in all cities joined in on the flash mobs and distributed tens of thousands of samples of ANEW Clinical Pro Line Eraser Treatment, which launches this month across the country.
“I can never turn down an opportunity to dance—especially when it’s celebrating such an exciting new innovation like Pro Line Eraser Treatment,” says Smirnoff. “I’m so thrilled to be a part of this big moment for Avon and spending time with the Representatives and fans.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/52897-avon-anew-clinical-pro-line-eraser-treatment-skincare-dermatology
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced the expansion of Emdeon Clinical Exchange™, its technology-enabled solution designed to improve business and clinical outcomes and care continuity.
Emdeon Clinical Exchange encompasses products and services that are designed to unite healthcare communities. Today, hospitals, physicians, labs, payers and pharmacies use Emdeon’s leading healthcare information network to securely exchange health information over six billion times annually. These healthcare stakeholders are demanding greater connectivity to each other and the ability to facilitate comprehensive, end-to-end clinical information exchange.
To view Multimedia News Release, go to http://www.multivu.com/mnr/48120-emdeon-expands-clinical-information-exchange-capabilities
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
